Who we are? We are a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat. We employ more than 45,000 people in 80 offices around the world, and market our products in 169 countries. More briefed (if needed): "Founded in 1923 and headquartered just outside Copenhagen, Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases."
CSL Behring's portfolio of innovative medicines includes a wide range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha 1 Antitrypsin Deficiency.
At Sanofi, we chase the miracles of science to improve people’s lives. Scientific discoveries don’t happen overnight or without hard work. But our determination to find answers for patients motivates us to develop breakthrough medicines and vaccines. And to never settle. From our beginning as a local French enterprise to our position as a leading global healthcare company, reinvention is in our DNA and reflects our quest to make life better for patients, partners, communities, and our own people. Today, we are one company, driven by a unifying purpose and a common ambition. We believe our cutting-edge science and manufacturing, fueled by data and digital technologies, have the potential to transform the practice of medicine, turning the impossible into possible for millions of people around the world. Progress brings us together and drives us to grow, to learn, and to collectively push our limits.